Navigation Links
Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City
Date:9/13/2011

BETHLEHEM, Pa., Sept. 13, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Edward L. Erickson, president and CEO of Saladax, will be presenting at the Annual UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City on Tuesday, September 20, 2011 at 12:30 p.m. EDT. The company will also be available for one-on-one meetings during the day.  The management presentation will include an overview of the company's business strategy, commercialization progress, products, strategic alliances and development pipeline.

The UBS Global Life Sciences Conference is among the largest healthcare investor conferences in the world.  Senior executives from the leading pharmaceutical, biotechnology and medical technology companies will provide their insight and outlook on the global life sciences industry.

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems.  In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.  For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.

Saladax Biomedical, Inc.
Edward L. Erickson
President and Chief Executive Officer
eerickson@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Jason Rando
jrando@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
2. Saladax Biomedical, Inc. Announces European Commercialization Team
3. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
4. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
5. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
6. Metabolic Solutions Development Company Presents New Brown Fat Research at the European Association for the Study of Diabetes
7. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
8. Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
9. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
10. Americord Registry Presents Abstract on Stem Cell Collection Method at 2011 COSTEM Conference and AABB Meeting
11. Debiopharm Group™ Presents the Debiopharm Group™ Life Sciences Award 2011 and two Junior Debiopharm Group™ Awards 2011 at the ISREC 2011 Life Sciences Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Dovetail Genomics™ LLC today announced ... program for a planned metagenomic genome assembly service. ... metagenomic genome assembly method in a talk on Friday, ... & Technology conference in Orlando, Fla. ... complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... MIAMI (PRWEB) , ... February 11, 2016 , ... ... in regenerative medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells ... researchers and phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican ...
(Date:2/10/2016)... , Feb. 10, 2016  The Maryland House of ... has announced that University of Maryland School of Medicine ... and University of Maryland Medical System President and CEO ... "Speaker,s Medallion," the highest honor given to the public ... Dean Reece and Mr. Chrencik for ...
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 This BCC Research ... market by reviewing the recent advances in high ... drive the field forward. Includes forecast through 2019. ... the challenges and opportunities that exist in the ... solution developers, as well as IT and bioinformatics ...
(Date:2/1/2016)... , February 1, 2016 ... advancements to drive global touchfree intuitive gesture control market ... --> Rising sales of consumer electronics coupled with ... control market size through 2020 ... electronics coupled with new technological advancements to drive global ...
(Date:1/25/2016)...   Unisys Corporation (NYSE: UIS ) today announced ... International Airport, New York City , to help ... to enter the United States using passports ... pilot testing of the system at Dulles last year. The ... during January 2016. --> pilot testing of the ...
Breaking Biology News(10 mins):